Unit of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital Materno-infantil Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Gynecol Oncol. 2011 Mar;120(3):353-7. doi: 10.1016/j.ygyno.2010.12.336. Epub 2011 Jan 6.
The aim of this study was to investigate the feasibility of the sentinel lymph node (SLN) identification with SPECT/CT lymphoscintigraphy imaging in the early stage invasive cervical cancer in patients undergoing radical hysterectomy and pelvic lymphadenectomy.
Between March 2007 and June 2009, a prospective consecutive study was designed for SLN mapping. Twenty-two patients with cervical cancer FIGO stage IB1 (n=20) or stage IIA1 (n=2) underwent SLN identification with preoperative SPECT/CT and planar images (technetium-99m colloid albumin injection around the tumor) and posterior intraoperative detection with both blue dye and a handheld or laparoscopic gamma probe. Complete pelvic lymphadenectomy was performed in all cases by open (n=2) or laparoscopic (n=20) surgery.
In the present series, a total of 35 SLN were detected with planar images and 40 SLN were identified and well located by SPECT/CT lymphoscintigraphy (median 2.0 nodes per patient). In 5/22 patients (22.7%) SPECT/CT procedure improves the number of localized SLN. Intraoperatively, 57 SLNs were identified, with a median of 3 SLNs per patient by gamma probe (a total of 53 hot nodes) and a median of 2 nodes per patient after blue dye injection (a total of 42 blue nodes). Microscopic nodal metastases (eight nodes, corresponding to four patients) were confirmed in 18.18% of cases; all these lymph nodes were previously detected as SLN. The remaining 450 nodes, including SLNs, following complete pelvic lymphadenectomy, were histologically negative.
Sentinel lymph node detection is improved by SPECT/CT imaging because of the increased number of SLN detected and the better tridimensional anatomic location, allowing easier intra-operative detection with gamma probe and showing, in this series, a 100% negative predictive value.
本研究旨在探讨在接受根治性子宫切除术和盆腔淋巴结清扫术的早期浸润性宫颈癌患者中,使用单光子发射计算机断层扫描(SPECT)/CT 淋巴闪烁成像进行前哨淋巴结(SLN)识别的可行性。
2007 年 3 月至 2009 年 6 月,我们进行了一项前瞻性连续研究,旨在进行 SLN 定位。22 例FIGO 分期为 IB1 期(n=20)或 IIA1 期(n=2)的宫颈癌患者接受了术前 SPECT/CT 和平面图像(肿瘤周围注射锝-99m 胶体白蛋白)以及术中使用蓝染和手持式或腹腔镜伽马探针进行的 SLN 检测。所有患者均接受了开放(n=2)或腹腔镜(n=20)手术的完全盆腔淋巴结清扫术。
在本系列中,共通过平面图像检测到 35 个 SLN,通过 SPECT/CT 淋巴闪烁成像识别和准确定位了 40 个 SLN(中位数为每个患者 2.0 个)。在 5/22 例患者(22.7%)中,SPECT/CT 检查程序增加了 SLN 的定位数量。术中共识别出 57 个 SLN,伽马探针的中位数为每个患者 3 个(共 53 个热节点),蓝染后的中位数为每个患者 2 个(共 42 个蓝染节点)。在 18.18%的病例中,确认了 8 个淋巴结(4 例患者)存在微观淋巴结转移,所有这些淋巴结均为之前检测到的 SLN。在完全盆腔淋巴结清扫后,包括 SLN 在内的 450 个淋巴结在组织学上均为阴性。
SPECT/CT 成像可提高 SLN 的检出数量和更好的三维解剖定位,从而提高 SLN 检测的成功率,使术中使用伽马探针更容易进行检测,并在本系列中显示出 100%的阴性预测值。